Tallimustine in advanced previously untreated colorectal cancer, a phase II study
1996

Tallimustine in Advanced Colorectal Cancer

Sample size: 17 publication Evidence: low

Author Information

Author(s): CJA Punt, Y Humblet, E Roca, LY Dirix, R Wainstein, A Polli, I Corradino

Primary Institution: University Hospital Nijmegen

Hypothesis

Does tallimustine have anti-tumour activity in previously untreated patients with advanced colorectal cancer?

Conclusion

Tallimustine showed no anti-tumour activity in patients with advanced colorectal cancer despite its unique mechanism of action.

Supporting Evidence

  • 17 patients were enrolled in the study.
  • 14 evaluable patients showed no responses.
  • Toxicity mainly consisted of neutropenia.

Takeaway

Tallimustine is a new cancer drug, but it didn't help patients with advanced colorectal cancer in this study.

Methodology

Phase II study with 17 previously untreated patients receiving tallimustine via i.v. bolus infusions every 4 weeks.

Limitations

No responses were documented in 14 evaluable patients, indicating a lack of efficacy.

Participant Demographics

13 males and 4 females, median age 58 years.

Statistical Information

Confidence Interval

0-23%

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication